

Catalogue Number	Product	Order number / Unit
------------------	---------	---------------------

9925 DCFPyL reference standard

Reference standard for [¹⁸F]DCFPyL
2-(3-{1-carboxy-5-[(6-[¹⁸F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid

Research Chemical

The tracer [¹⁸F]DCFPyL is patent-protected in some countries, please consider to inquire for PSMA-1007 compounds (ID 9943, 99433) instead, that are provided by ABX under exclusive licence.

Molar Mass: 442.40

C₁₈H₂₃FN₄O₈

[1423758-00-2]

Colourless to off-white solid packaged in dark glass screw cap vials.

Purity: ≥ 95 %

Certificates:

CoA; ¹H and ¹⁹F NMR spectra (identity); HPLC (purity)

Chemical Name:

2-(3-{1-carboxy-5-[(6-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid

Synonymes:

[¹⁸F]DCFPyL standard; 2-(3-{1-Carboxy-5-[(6-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid

Literature:

Chen Y. et al. 2-(3-{1-Carboxy-5-[(6-[¹⁸F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [¹⁸F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer. Clin. Cancer. Res. 2011, 17, 7645-7653.

Szabo Z. et al. Initial Evaluation of [¹⁸F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol. Imaging Biol. 2015, 17, 565-574.

Rowe S.P. et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann. Nucl. Med. 2015, 29, 877-882.

Rowe S.P. et al. Detection of ¹⁸F-FDG PET/CT occult lesions with ¹⁸F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin. Nucl. Med. 2016, 41, 83-85.

Dietlein M. et al. Comparison of [¹⁸F]DCFPyL and [⁶⁸Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol. Imaging Biol. 2015, 17, 575-584.

9925.0005: 5 mg per vial
 9925.0010: 10 mg per vial
 Please inquire for customized filling and bulk quantities.

